Literature DB >> 8620502

Interaction of ionizing radiation with paclitaxel (Taxol) and docetaxel (Taxotere) in HeLa and SQ20B cells.

C Hennequin1, N Giocanti, V Favaudon.   

Abstract

Altered gamma-ray response by brief (1 h), concomitant exposure to paclitaxel (Taxol) or docetaxel (Taxotere) was investigated in growing HeLa and SQ20B human tumor cells in vitro. For both cell lines, both taxoids were able to reduce or enhance radiation cell killing, depending on the drug concentration. Large reduction of radiosensitivity (up to 3.3-fold reduction relative to radiation alone) was observed in HeLa cells over a wide range of drug concentrations, extending to 1.5- (paclitaxel) or 3.3- fold (docetaxel) the IC50s determined for drug alone. This antagonistic effect was also observed with SQ20B cells. It disappeared for drug concentrations exceeding 0.9 (SQ20B), 1.6 (HeLa; paclitaxel), and 3.4 (HeLa; docetaxel) IC50 equivalents, above which a drug dose-dependent, supra-additive radiation-drug interaction was observed. Reduction of radiation susceptibility in the low-drug dose range also held for mid-G1 synchronized HeLa cells, i.e., in the cell cycle compartment characterized as the most resistant one to docetaxel (C. Hennequin et al., Br. J. Cancer, 71: 1194-1198, 1995). In the case of SQ20B cells, the cytotoxicity of either drug or radiation alone was primarily dependent on the state of growth, with quiescent (G(0)) cells showing increased radiosensitivity and reduced drug toxicity compared to the growing fraction. The effect of taxoids (1-h contact) was finally investigated in sequential treatment as a function of the time elapsed between radiation and exposure to drugs. In HeLa cells, the postirradiation time-dependence of the response to combined treatment was biphasic. The radioprotecting potential of either taxoid disappeared in approximately 1.5 h following radiation. At longer postirradiation delays, radiation-induced redistribution in the cell cycle appeared to be the major determinant of HeLa cell survival, in relation to the differential cell cycle phase specificity of each drug. Pronounced paclitaxel recovery versus increased sensitivity to docetaxel occurred over 8 h after irradiation. SQ20B cells showed monophasic radiation recovery with both drugs over the same time range.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8620502

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  38 in total

Review 1.  Advanced non-small cell lung carcinoma: the emerging role of docetaxel.

Authors:  C J Langer
Journal:  Invest New Drugs       Date:  2000-02       Impact factor: 3.850

Review 2.  Docetaxel: a review of its use in non-small cell lung cancer.

Authors:  A M Comer; K L Goa
Journal:  Drugs Aging       Date:  2000-07       Impact factor: 3.923

3.  Interstitial docetaxel (taxotere), carmustine and combined interstitial therapy: a novel treatment for experimental malignant glioma.

Authors:  Prakash Sampath; Laurence D Rhines; Francesco DiMeco; Betty M Tyler; Michael C Park; Henry Brem
Journal:  J Neurooncol       Date:  2006-04-25       Impact factor: 4.130

4.  Cell cycle perturbations and radiosensitization effects in a human prostate cancer cell line.

Authors:  Albert A Geldof; Marian A B D Plaizier; Ilse Duivenvoorden; Marieke Ringelberg; Richard T Versteegh; Don W W Newling; Gerrit J J Teule
Journal:  J Cancer Res Clin Oncol       Date:  2003-03-18       Impact factor: 4.553

5.  Phase I/II dose escalation study of docetaxel and carboplatin combination supported with amifostine and GM-CSF in patients with incomplete response following docetaxel chemo-radiotherapy: additional chemotherapy enhances regression of residual cancer.

Authors:  M I Koukourakis; A Giatromanolaki; S Kakolyris; M Froudarakis; V Georgoulias; G Retalis; N Bahlitzanakis
Journal:  Med Oncol       Date:  2000-05       Impact factor: 3.064

6.  The effect of paclitaxel on the radiosensitivity of gynecological tumor cells.

Authors:  M Rave-Fränk; H Meden; A Jäschke; A Tänzer; O Boghun; R Fietkau
Journal:  Strahlenther Onkol       Date:  1997-05       Impact factor: 3.621

7.  Salivary gland carcinoma treated with concomitant chemoradiation with intraarterial cisplatin and docetaxel.

Authors:  Shin-ichiro Maruya; Atsushi Namba; Atsushi Matsubara; Seiji Kakehata; Ikuko Takeda; Takashi Shirasaki; Yoshiomi Hatayama; Morio Nagahata; Junkichi Yokoyama; Hideichi Shinkawa
Journal:  Int J Clin Oncol       Date:  2006-10       Impact factor: 3.402

8.  Radiation-sensitizing effect of low-concentration docetaxel on human esophageal squamous cell carcinoma cell lines.

Authors:  Satoshi Tabuchi; Soji Ozawa; Kazuo Koyanagi; Naoyuki Shigematsu; Atsushi Kubo; Masakazu Ueda; Yuko Kitagawa; Masaki Kitajima
Journal:  Exp Ther Med       Date:  2011-05-10       Impact factor: 2.447

Review 9.  Pharmacotherapy options for locally advanced and advanced cervical cancer.

Authors:  Alfonso Dueñas-González; Lucely Cetina; Jaime Coronel; Déborah Martínez-Baños
Journal:  Drugs       Date:  2010-03-05       Impact factor: 9.546

10.  Phase I Study to Determine MTD of Docetaxel and Cisplatin with Concurrent Radiation Therapy for Stage III Non-Small Cell Lung Cancer.

Authors:  You-Quan Li; An-Hui Shi; Fu-Hai Li; Rong Yu; Guang-Ying Zhu
Journal:  Chin J Cancer Res       Date:  2011-06       Impact factor: 5.087

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.